MIST
Milestone Pharmaceuticals Inc.
Biotechnology
Market Cap$201M
5Y Perf.-40.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MIST vs XENE
Revenue, margins, valuation, and 5-year total return — side by side.
XENE
Xenon Pharmaceuticals Inc.
Biotechnology
Market Cap$4.42B
5Y Perf.+308.8%
MIST vs XENE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MIST | XENE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $201M | $4.42B |
| Revenue (TTM) | $1M | $0.00 |
| Net Income (TTM) | $-79M | $-383M |
| Gross Margin | -5.6% | 66.1% |
| Operating Margin | -43.4% | -49.7% |
| Total Debt | $58M | $8M |
| Cash & Equiv. | $73M | $199M |
MIST vs XENE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MIST
XENE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Milestone Pharmaceu… (MIST) | 100 | 59.8 | -40.2% |
| Xenon Pharmaceutica… (XENE) | 100 | 408.8 | +308.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MIST vs XENE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XENE leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Milestone Pharmaceuticals Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
MIST
Milestone Pharmaceuticals Inc.
The Growth Play
MIST is the clearest fit if your priority is growth exposure.
- EPS growth -11.9%, 3Y rev CAGR -32.4%
- -93.9% revenue growth vs XENE's -100.0%
Best for: growth exposure
XENE
Xenon Pharmaceuticals Inc.
The Income Pick
XENE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.05
- 7.4% 10Y total return vs MIST's -87.7%
- Lower volatility, beta 1.05, Low D/E 1.4%, current ratio 13.42x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MIST | -93.9% revenue growth vs XENE's -100.0% |
| Quality / Margins | XENE | -46.1% margin vs MIST's -55.3% |
| Stability / Safety | XENE | Beta 1.05 vs MIST's 2.11, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XENE | +58.5% vs MIST's +46.5% |
| Efficiency (ROA) | XENE | -42.0% ROA vs MIST's -102.2%, ROIC -55.3% vs -133.7% |
MIST vs XENE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2022
MIST vs XENE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXENELAGGINGMIST
MISTMilestone Pharmaceuti…
2leads
XENEXenon Pharmaceuticals…
3leads
6 Total Categories
CATEGORYLEADERvs MISTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MIST3/5
Valuation MetricsMultiples, price ratios, and targets
MIST2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XENE8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
XENE6/6
Risk & VolatilityBeta, volatility, and downside exposure
XENE2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MIST leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
MIST and XENE operate at a comparable scale, with $1M and $0 in trailing revenue. XENE is the more profitable business, keeping -46.1% of every revenue dollar as net income compared to MIST's -55.3%.
| Metric | MISTMilestone Pharmac… | XENEXenon Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $1M | $0 |
| EBITDAEarnings before interest/tax | -$62M | -$411M |
| Net IncomeAfter-tax profit | -$79M | -$383M |
| Free Cash FlowCash after capex | -$49M | -$307M |
| Gross MarginGross profit ÷ Revenue | -5.6% | +66.1% |
| Operating MarginEBIT ÷ Revenue | -43.4% | -49.7% |
| Net MarginNet income ÷ Revenue | -55.3% | -46.1% |
| FCF MarginFCF ÷ Revenue | -34.2% | -37.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.0% | -41.0% |
MIST leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
MIST leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | MISTMilestone Pharmac… | XENEXenon Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $201M | $4.4B |
| Enterprise ValueMkt cap + debt − cash | $186M | $4.2B |
| Trailing P/EPrice ÷ TTM EPS | -2.52x | -12.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 129.88x | 589.47x |
| Price / BookPrice ÷ Book value/share | 3.80x | 7.63x |
| Price / FCFMarket cap ÷ FCF | — | — |
MIST leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
XENE leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
XENE delivers a -49.2% return on equity — every $100 of shareholder capital generates $-49 in annual profit, vs $-8 for MIST. XENE carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to MIST's 1.40x. On the Piotroski fundamental quality scale (0–9), XENE scores 4/9 vs MIST's 2/9, reflecting mixed financial health.
| Metric | MISTMilestone Pharmac… | XENEXenon Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -8.3% | -49.2% |
| ROA (TTM)Return on assets | -102.2% | -42.0% |
| ROICReturn on invested capital | -133.7% | -55.3% |
| ROCEReturn on capital employed | -74.4% | -43.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 1.40x | 0.01x |
| Net DebtTotal debt minus cash | -$15M | -$191M |
| Cash & Equiv.Liquid assets | $73M | $199M |
| Total DebtShort + long-term debt | $58M | $8M |
| Interest CoverageEBIT ÷ Interest expense | -5.71x | — |
XENE leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
XENE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XENE five years ago would be worth $30,254 today (with dividends reinvested), compared to $3,298 for MIST. Over the past 12 months, XENE leads with a +58.5% total return vs MIST's +46.5%. The 3-year compound annual growth rate (CAGR) favors XENE at 9.6% vs MIST's -21.6% — a key indicator of consistent wealth creation.
| Metric | MISTMilestone Pharmac… | XENEXenon Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -7.8% | +25.9% |
| 1-Year ReturnPast 12 months | +46.5% | +58.5% |
| 3-Year ReturnCumulative with dividends | -51.8% | +31.8% |
| 5-Year ReturnCumulative with dividends | -67.0% | +202.5% |
| 10-Year ReturnCumulative with dividends | -87.7% | +737.1% |
| CAGR (3Y)Annualised 3-year return | -21.6% | +9.6% |
XENE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
XENE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XENE is the less volatile stock with a 1.05 beta — it tends to amplify market swings less than MIST's 2.11 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XENE currently trades 87.6% from its 52-week high vs MIST's 61.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MISTMilestone Pharmac… | XENEXenon Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.11x | 1.05x |
| 52-Week HighHighest price in past year | $3.06 | $63.95 |
| 52-Week LowLowest price in past year | $1.00 | $28.19 |
| % of 52W HighCurrent price vs 52-week peak | +61.8% | +87.6% |
| RSI (14)Momentum oscillator 0–100 | 58.2 | 61.3 |
| Avg Volume (50D)Average daily shares traded | 2.1M | 1.5M |
XENE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MIST as "Buy" and XENE as "Buy". Consensus price targets imply 287.8% upside for MIST (target: $7) vs 43.2% for XENE (target: $80).
| Metric | MISTMilestone Pharmac… | XENEXenon Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $7.33 | $80.20 |
| # AnalystsCovering analysts | 7 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XENE leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). MIST leads in 2 (Income & Cash Flow, Valuation Metrics).
Best OverallXenon Pharmaceuticals Inc. (XENE)Leads 3 of 6 categories
Loading custom metrics...
MIST vs XENE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MIST or XENE a better buy right now?
Analysts rate Milestone Pharmaceuticals Inc.
(MIST) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MIST or XENE?
Over the past 5 years, Xenon Pharmaceuticals Inc.
(XENE) delivered a total return of +202. 5%, compared to -67. 0% for Milestone Pharmaceuticals Inc. (MIST). Over 10 years, the gap is even starker: XENE returned +737. 1% versus MIST's -87. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MIST or XENE?
By beta (market sensitivity over 5 years), Xenon Pharmaceuticals Inc.
(XENE) is the lower-risk stock at 1. 05β versus Milestone Pharmaceuticals Inc. 's 2. 11β — meaning MIST is approximately 101% more volatile than XENE relative to the S&P 500. On balance sheet safety, Xenon Pharmaceuticals Inc. (XENE) carries a lower debt/equity ratio of 1% versus 140% for Milestone Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — MIST or XENE?
On earnings-per-share growth, the picture is similar: Milestone Pharmaceuticals Inc.
grew EPS -11. 9% year-over-year, compared to -44. 9% for Xenon Pharmaceuticals Inc.. Over a 3-year CAGR, XENE leads at -7. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MIST or XENE?
Xenon Pharmaceuticals Inc.
(XENE) is the more profitable company, earning -46. 1% net margin versus -55. 3% for Milestone Pharmaceuticals Inc. — meaning it keeps -46. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MIST leads at -40. 2% versus -49. 7% for XENE. At the gross margin level — before operating expenses — XENE leads at 66. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MIST or XENE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MIST or XENE better for a retirement portfolio?
For long-horizon retirement investors, Xenon Pharmaceuticals Inc.
(XENE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 05), +737. 1% 10Y return). Milestone Pharmaceuticals Inc. (MIST) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XENE: +737. 1%, MIST: -87. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MIST and XENE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.